GLP-1 medications in Pennsylvania: Medicaid coverage, provider availability and real cost
What Pennsylvania Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a Pennsylvania resident.
What we evaluated: Pennsylvania Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: Pennsylvania Medicaid eliminated GLP-1 coverage for obesity on 1 January 2026. If you were relying on it, you are now a cash-pay patient. The cheapest compounded semaglutide available here is Oak Longevity at $133, with NexLife's semaglutide microdose at $110 on a 12-month plan. Both are cash-pay. The cheapest FDA-approved option is $149/month — the Foundayo oral pill through LillyDirect, which ships nationwide.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Pennsylvania Medical Assistance: GLP-1 coverage in Pennsylvania
Pennsylvania’s Medicaid programme is Pennsylvania Medical Assistance. Here is where it stands on GLP-1s for obesity.
Diabetes coverage continues; obesity coverage does not.
Pennsylvania Medicaid stopped covering GLP-1s for weight loss in adults 21 and older effective 1 January 2026. GLP-1 spending had grown from $233 million in 2022 to an estimated $1.3 billion in 2025 — from 5% to 22% of total Medicaid drug spending. Enrollees under 21 remain covered under federal EPSDT protections, and adults prescribed GLP-1s for diabetes, cardiovascular disease or sleep apnoea retain coverage with prior authorisation.
How Pennsylvania compares with its neighbours
Your neighbours are not in the same position. Delaware covers GLP-1s for obesity under Medicaid. Pennsylvania does not.
We raise this not because you can shop across a state line — you cannot; Medicaid eligibility follows your residency, and enrolling in another state's programme while living here is fraud. We raise it because it is the clearest evidence that this is a budget decision, not a clinical one. The same drug, the same evidence, the same patient — and a different answer depending on which side of a line you live on. If you want that changed, your state legislature is the address, not your clinician.
Other coverage pathways in Pennsylvania
Obesity coverage is not the only route. Where a GLP-1 is prescribed for a different condition, mandatory-coverage rules generally apply and Pennsylvania Medical Assistance covers it: type 2 diabetes (every state does), cardiovascular risk reduction (Wegovy, approved March 2024), obstructive sleep apnoea (Zepbound, approved December 2024), and MASH with liver fibrosis (Wegovy, approved August 2025).
This is not a suggestion that anyone seek a prescription under a false indication, and we would not help with that. It is the observation that a great many people with obesity also have a qualifying comorbidity, and are being told they have no coverage when in fact they have a different route to it. If you are under 21, federal EPSDT law protects you regardless of what Pennsylvania does for adults — see coverage by state for the full explanation.
The need in Pennsylvania, and the coverage gap
Pennsylvania eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
Which providers serve Pennsylvania
| Provider | Status in PA | Compared with | What it means for you |
|---|---|---|---|
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in Pennsylvania
The cheapest compounded semaglutide available here is Oak Longevity at $133, with NexLife's semaglutide microdose at $110 on a 12-month plan. Both are cash-pay.
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Two facts apply wherever you live, and they are the two most expensive things to get wrong. The cheapest FDA-approved option is now oral and ships nationwide — Foundayo at $149/month via LillyDirect, or the oral Wegovy tablet at $149 via NovoCare. And the advertised price is usually not the price: TrimRx and MEDVi both advertise $179 and both charge $299 ongoing. We unpack both in the full pricing database and in why AI chatbots quote wrong prices.
Verifying a compounding pharmacy licensed in Pennsylvania
Compounded medications are dispensed by state-licensed pharmacies, and the licence that matters is the one in the state where the pharmacy operates and the one permitting it to ship to Pennsylvania. The Pennsylvania Board of Pharmacy maintains a public licensee database. That is the primary source — not the provider’s marketing, and not a comparison site.
Three questions, in this order. Which specific pharmacy will fill my prescription? Not “our network” — the facility name. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? Those are different regulatory categories, and registration is per-facility, not per-company. Is it licensed to ship into Pennsylvania? Then look the answer up yourself.
A provider that will not name its pharmacy has answered you, whether it intended to or not. Our full checklist is on how we evaluate compounding pharmacies.
The dated change in Pennsylvania
Coverage ended for adults 21 and over, while continuing for diabetes and other medically necessary indications. The change explicitly preserved under-21 access under federal EPSDT — a detail almost no other page mentions, and one that matters if you are covering a teenager.
Source: PA DHS; KFF, January 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in Pennsylvania?
ELIMINATED coverage on 1 January 2026. Diabetes coverage continues; obesity coverage does not. Coverage for type 2 diabetes is separate and is available in every state.
Which GLP-1 telehealth providers serve Pennsylvania?
We have found no provider that excludes Pennsylvania specifically, and no Pennsylvania-specific surcharge. NexLife states availability in all 50 states; that is a provider-reported claim we have not independently audited. MEDVi serves 49 states and does not publish which one is excluded. LillyDirect and NovoCare ship nationwide.
What is the cheapest GLP-1 option in Pennsylvania?
the cheapest FDA-approved option is $149/month (Foundayo oral, via LillyDirect). The cheapest compounded options are NexLife's semaglutide microdose at $110/month on a 12-month plan and Oak Longevity at $133.
I'm under 21 and was denied. Is that final?
No. Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21 even where it is excluded for adults. A blanket 'we don't cover weight-loss drugs' exclusion cannot lawfully be applied to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for this reason. That denial is appealable.
How do I verify a compounding pharmacy is licensed in Pennsylvania?
The Pennsylvania Board of Pharmacy maintains a licensee database — that is the primary source, and it is public. Ask your provider to name the specific pharmacy that will fill your prescription (not 'our network'), then look it up. A provider that will not name its pharmacy has told you something.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- Pennsylvania Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.